AzTrials
AzTrials

NSCLCPhase 3NCT02954172

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

A Phase 3 study testing Bevacizumab in Combination With Paclitaxel/Carboplatin and IBI305 in Combination with Paclitaxel/Carboplatin in people with NSCLC, run by Innovent Biologics (Suzhou) Co. Ltd. at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A randomized, double blind, multicenter phase3 study . Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
NSCLC
What is being tested?
Bevacizumab in Combination With Paclitaxel/Carboplatin and IBI305 in Combination with Paclitaxel/Carboplatin
Could I receive a placebo?
No, everyone receives an active treatment
How many people
450 participants
Where
1 siteChina
Study dates
28 Nov 2016to 12 Nov 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • signed inform consent form(ICF)
  • Age ≥ 18 years and ≤ 75 years, male or female
  • Histologically or cytologically documented inoperable, local advanced (stage IIIB), metastatic (stage IV), or recurrent non-squamous NSCLC; Mixed tumors should be categorized according to the predominant cell type
  • Histologically confirmed epidermal growth factor receptor (EGFR) wild type or insensitive mutation
  • At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors（RECISIT） v 1.1
  • Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1
Show all 14Show fewer
  • Life expectancy ≥ 6 months
  • Laboratory results:
  • Adequate hematologic function, defined as absolute neutrophil count ≥1.5×10^9 /L, platelet count ≥100 ×10^9 /L, hemoglobin ≥90g/L;
  • Adequate liver function, defined as total bilirubin levels ≤ 1.5 times normal upper limit (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times ULN, or AST and ALT levels ≤ 5 times ULN for patients with hepatic metastasis;
  • Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 ml / min (Cockcroft-Gault formula) and proteinuria < 2+;
  • Coagulation function is adequate, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN), PTT or aPTT ≤ 1.5 times ULN;
  • Expected protocol compliance
  • Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for 6 months after receiving last study treatment (e.g. abstinence, sterilization surgery, oral contraceptives, contraception by progesterone injection or subcutaneous).

Who cannot join

  • Prior chemotherapy or target therapy with another systemic anti-cancer agent (e.g., monoclonal antibody, tyrosine kinase inhibitor) for the treatment of the patient's current stage of disease (Stage IIIB not amenable for combined modality treatment, stage IV or recurrent disease). Prior surgery and irradiation is permitted, provided that the criteria outlined in the protocol for both treatments are met. Disease progressed within 6 months after adjuvant therapy must be excluded.
  • Mixed non-small cell and small cell carcinoma, or mixed adenosquamous carcinomas with predominant squamous cell
  • Histologically or cytologically confirmed EGFR sensitive mutation type, unknown EGFR status for any reason is allowed in this study.
  • Known hemoptysis within 3 months prior to screening with blood volume more than 2.5 mL each time
  • Evidence of tumor invading major blood vessels on imaging. The investigator or the local radiologist must exclude evidence of tumor that is fully contiguous with, surrounding, or extending into the lumen of a major blood vessel (e.g., pulmonary artery or superior vena cava)
  • Evidence of brain metastasis, spinal cord compression or carcinomatous meningitis history with clinical symptoms. For stable patients with no symptom, could be admitted if fulfill all below criteria: measurable lesion(s) out of CNS, no metastasis at mesocephalon, annular protuberance, medulla oblongata and spinal cord; no history of intracranial bleeding.
Show all 28Show fewer
  • Radical radiotherapy to the thorax with curative intent within 28 days prior to enrollment; palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to first dose of study treatment.
  • Serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of the study.
  • Minor surgery (Including insertion of an indwelling catheter) within 48 hours prior to first dose of study treatment
  • Recent or current (within 10 days prior to first dose of study treatment) receive treatment of Aspirin (> 325 mg/day) or other non-steroidal anti-inflammatory drugs (NSAID) known to inhibit platelet function (within 10 days prior to first dose of study treatment)
  • Recent or current receive treatment of oral all doses of oral or parenteral anticoagulants or thrombolytic agent. Prophylactic use of anticoagulants is permitted.
  • History or evidence of inherited bleeding diathesis or coagulopathy or thrombus
  • Uncontrolled hypertension (SBP>140 mmHg and/or diastolic blood pressure>90 mmHg), prior history of hypertensive crisis and hypertensive encephalopathy
  • Clinically significant cardiovascular disease but not limited to active infections; unstable angina; stroke or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening) ; congestive heart-failure (New York Heart Association (NYHA) class≥ II) ; serious cardiac arrhythmia, hepatic, renal or metabolic disease requiring medication during the study.
  • History of peptic ulcer, gastrointestinal perforation, erosive esophagitis, erosive gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula or intra-abdominal abscess within 6 months prior to screening
  • Patient diagnosed with a tracheo-esophageal fistula
  • Clinically significant third space effusion (e.g., uncontrolled ascites or pleural effusion by extraction or other treatment)
  • Pulmonary fibrosis or active pneumonia showed by CT at baseline
  • Active malignancy other than non-small cell lung cancer (NSCLC), treated carcinoma in situ of the cervix, superficial basal cell or squamous cell carcinoma, radical surgery of localized prostate cancer, radical surgery of ductal carcinoma in situ within 5 years prior to randomization
  • Known autoimmune disease
  • Known positive HbsAg and hepatitis B virus (HBV)-DNA drop test in peripheral blood ≥ 1 x 10^3 copy number/L or 200 IU/mL; If HBsAg positive and HBV-DNA drop test in peripheral blood < 1 x 10^3 copy number/L or 200 IU/mL, patient is considered to be eligible by investigator only when chronic hepatitis B in the plateau and do not increase the risk
  • Known positive HIV or hepatitis C virus (HCV) or syphilis
  • Known allergic disease or allergic physique
  • Treatment with any other investigational agent or participation in another clinical trial within 30 days prior to screening
  • Known alcoholism or drug abuse
  • Pregnant or anticipation of pregnant during the study or lactating women
  • Known hypersensitivity to bevacizumab or any of its excipients and/or any of the chemotherapy agents
  • Other conditions that the investigator thinks unsuitable in this study

Trial locations and contacts

1 site in 1 country.

China1 site

  • Cancer Center; Sun Yat sen University;

    Guangzhou, Guangdong, 510060

Other trials in China

About this study

Official title: Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC

A randomized, double blind, multicenter phase3 study .

Read the detailed description

A randomized, double blind, multicenter phase3 study in chemotherapy naive patients with stage IIIB,IV or recurrent NSCLC of non-squamous. the study will randomize about 436 patients at a 1:1 ratio to 2 treatment arms. The study is divided 4 phase, screening, combination treatment, maintenance and follow up.

Conditions
NSCLC
Being tested
Bevacizumab in Combination With Paclitaxel/Carboplatin, IBI305 in Combination with Paclitaxel/Carboplatin

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bevacizumab in Combination With Paclitaxel/CarboplatinDrug

    Also called Avastin

    Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

  • IBI305 in Combination with Paclitaxel/CarboplatinDrug

    Also called Bevacizumab Biosimilar

    Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

Study groups in NCT02954172
Study groupRoleWhat they receive
Bevacizumab in Combination With Paclitaxel/CarboplatinExperimentalDrug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
Receives: Drug: Bevacizumab in Combination With Paclitaxel/Carboplatin
IBI305 in Combination with Paclitaxel/CarboplatinActive comparatorDrug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
Receives: Drug: IBI305 in Combination with Paclitaxel/Carboplatin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective Response Rate

    ORR（objective response rate）was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR.

    Measured: 18 weeks

Secondary outcomes (2)

  1. Overall Survival Time

    OS was defined as the time from randomization to death due to any cause.

    Measured: 18.020 months

  2. Progression-free Survival

    Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by Independent Radiological Review Committee.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2016 (estimated)
  2. Study start28 Nov 2016
  3. Primary completion19 Oct 2018
  4. Study completion12 Nov 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
450 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02954172
Sponsor's protocol ID
CIBI305A301
Status last verified
Nov 2020
First submitted
23 Oct 2016
Last updated
8 Dec 2020
Data monitoring committee
No
Individual data sharing
Undecided

Publications

  • Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y, Wang L, Lu S, Chen G, Li B, Xie C, Fang J, Yang N, Zhang Y, Cui J, Song Y, Zhang C, Mei X, Cao B, Yang L, Cheng Y, Ying K, Sun T, Ren B, Yu Q, Liao Z, Pei Z, Wang M, Zhou J, Yu S, Feng G, Wan H, Wang H, Gao S, Wang J, An G, Geng Y, Ji Y, Yuan Y, Ma S, Jia Z, Hu M, Zhou H, Yu J, Sun X, Zhang L. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Transl Lung Cancer Res. 2019 Dec;8(6):989-999. doi: 10.21037/tlcr.2019.12.23.

    PubMed 32010577

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Bevacizumab in Combination With Paclitaxel/Carboplatin and IBI305 in Combination with Paclitaxel/Carboplatin in people with NSCLC, run by Innovent Biologics (Suzhou) Co. Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Dec 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Dec 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective Response Rate (time frame: 18 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02954172, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in